Dr. Marco Quarta, Ph.D. - Co-Founder and CEO - Rubedo Life Sciences; CEO, The Phaedon Institute

Dr. Marco Quarta, Ph.D. is Co-Founder and CEO of Rubedo Life Sciences ( https://www.rubedolife.com/ ), a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. The company's proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders.

Dr. Quarta received his doctorate degree in Biotechnology from the University of Bologna and a Ph.D. in Neuroscience from the University of Padua. He completed a post-doc in Aging and Stem cell Biology in the lab of Prof. Thomas Rando at Stanford University and continued his work at Stanford directing a research team at the Center for Tissue Regeneration, Repair, and Restoration at the VA Hospital in Palo Alto, CA. While there, he established a translational program in regenerative medicine. He has over 35 publications and patents in the field of aging, stem cells, regenerative medicine, and rejuvenation.

Dr. Quarta also co-founded Wetware Concepts, Young European Biotech Network (YEBN), and Turn Biotechnology, and served as an executive board member of the European Federation of Biotechnologies. He currently sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) Calpoly Bridge program, and the advisory board at the Center for Healthcare Innovation. He is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University, one of the most prestigious institutions supporting the science of aging.

Dr. Quarta also serves as CEO and President for the Board of Directors of The Phaedon Institute ( https://www.phaedon.institute/ ), a think-tank organization that operates with the mission of supporting and enabling effective and sustainable growth in the field of aging and longevity sciences.